Alamar Biosciences Raises 2026 Revenue Guidance

The company lifted full-year revenue outlook after biopharmaceutical clients became its largest customer segment.

Updated on Nov. 22, 2026 in Public Companies

Alamar Biosciences Raises 2026 Revenue Guidance

Live Poll

Do you trust biotech companies to deliver reliable medical testing tools?

Alamar Biosciences raised its full-year 2026 revenue guidance to between $121 million and $123 million during its third-quarter earnings webcast on November 3, 2026. Biopharmaceutical clients generated 49% of third-quarter revenue and became the company's largest customer segment for the first time.

Why it matters

The shift toward drug developers signals growing demand for the company's proteomics testing in long-term clinical trials, which generate repeat kit purchases. For the broader U.S. life sciences sector, the update points to recurring revenue models gaining weight among diagnostics firms.

Biopharmaceutical clients generated 49% of third-quarter revenue, and full-year 2026 revenue guidance now stands at $121 million to $123 million. The company did not address the revenue contribution expected from its ARGO HT/DX clinical instrument in these figures.

The players

Alamar Biosciences

A publicly traded life sciences company that develops proteomics testing platforms, including the NULISA system used in clinical research.

The details

During its third-quarter 2026 earnings webcast, Alamar Biosciences also reported selection for the U.K. Biobank Vanguard study, which will use its NULISA platform to profile 220 neurologically relevant proteins across 80,000 blood samples. The company said its ARGO HT/DX clinical instrument is in development.

Timeline

  1. November 3, 2026: Alamar Biosciences held its third-quarter 2026 earnings webcast call.

  2. 2026: Full-year revenue guidance was raised to $121 million to $123 million.

  3. Late 2027: The company plans to submit the ARGO HT/DX for FDA marketing authorization.

Market Landscape

The company's NULISA platform, now selected for the U.K. Biobank Vanguard study, is being applied to large-scale neurodegenerative biomarker profiling. Its growing biopharmaceutical customer base reflects drug developers moving toward proteomics-based trial monitoring.

For investors tracking the company, the revised guidance and rising biopharmaceutical share offer a clearer view of recurring revenue patterns. The company's planned FDA submission for its clinical instrument by late 2027 is the next milestone to monitor.

The takeaway

Recurring testing demand from long-term drug trials can provide more predictable revenue than one-time instrument sales. Watching how segment mix shifts in future quarters will show whether this pattern holds.

Further reading

For more corporate filings and market updates, explore Public Companies coverage on Wisevoter.

Source note: This article includes information reported by The Motley Fool.

Live Poll

Do you trust biotech companies to deliver reliable medical testing tools?